PUBLISHER: The Business Research Company | PRODUCT CODE: 1948283
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948283
Structural heart is a subspecialty within cardiology that concentrates on diagnosing and treating structural abnormalities or diseases of the heart, particularly those impacting the valves, chambers, and surrounding structures. This field typically involves minimally invasive procedures conducted in a catheterization laboratory as opposed to traditional open-heart surgery.
The primary categories of structural heart products encompass occluders, annuloplasty rings, heart valve balloons, and other related devices. Occluder systems are specifically designed to provide a conduit for delivering devices into the heart's chambers, coronary arteries, and peripheral vasculature. These devices are utilized in patients with specific types of atrial septal defects featuring right atrial or ventricle enlargement, preventing paradoxical embolism. The diverse procedures employing structural heart products include heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. These procedures cater to various end-users such as hospitals, ambulatory surgical centers, and cardiac centers.
Tariffs are influencing the structural heart market by increasing costs of imported catheters, imaging systems, delivery devices, and implantable components used in valve repair and closure procedures. Healthcare providers in North America and Europe are most affected due to reliance on advanced imported devices, while Asia-Pacific faces higher costs for exported cardiac technologies. These tariffs are elevating procedural expenses and slowing adoption in cost-sensitive regions. At the same time, they are encouraging local device manufacturing, regional R&D investments, and supply chain diversification.
The structural heart market research report is one of a series of new reports from The Business Research Company that provides structural heart market statistics, including structural heart industry global market size, regional shares, competitors with a structural heart market share, detailed structural heart market segments, market trends and opportunities, and any further data you may need to thrive in the structural heart industry. This structural heart market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The structural heart market size has grown strongly in recent years. It will grow from $15.89 billion in 2025 to $17.31 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing prevalence of valvular heart diseases, aging global population, expansion of catheterization laboratories, adoption of transcatheter heart technologies, rising awareness of minimally invasive cardiac care.
The structural heart market size is expected to see strong growth in the next few years. It will grow to $24.6 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growing demand for transcatheter therapies, increasing investments in structural heart programs, expansion of cardiac centers of excellence, advancements in device miniaturization, rising focus on reducing open-heart surgery rates. Major trends in the forecast period include increasing adoption of transcatheter valve procedures, rising use of minimally invasive structural heart interventions, growing integration of advanced cardiac imaging, expansion of catheter-based repair technologies, enhanced focus on patient-specific treatment planning.
The rising prevalence of cardiovascular disorders is expected to drive growth in the structural heart market in the coming years. Cardiovascular disorders are conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. This increase is primarily driven by aging populations, lifestyle and dietary changes, and rising rates of obesity and diabetes. Structural heart devices and services provide diagnosis and treatment for anomalies affecting the heart's valves, chambers, and surrounding tissues through minimally invasive procedures rather than open-heart surgery, enabling efficient treatment with lower complication risks. For example, in September 2025, the British Heart Foundation, a UK-based charity, reported that over 7.6 million people in the UK-more than 4 million men and over 3.6 million women-were living with cardiovascular disease, with projections suggesting the number could increase by about 1 million by 2030 and roughly 2 million by 2040 due to an aging population and improved survival rates. Thus, the rising prevalence of cardiovascular disorders is propelling the structural heart market.
Key players in the structural heart market are innovating advanced products, including transcatheter edge-to-edge repair (TEER) systems, to improve minimally invasive treatment options for heart valve diseases. TEER systems are minimally invasive medical devices designed to address heart valve conditions, particularly mitral valve regurgitation. For example, in April 2024, Abbott Laboratories, a US-based medical device firm, gained approval from the Food and Drug Administration (FDA), a US federal agency responsible for safeguarding public health, for its device called TriClip. TriClip is an innovative TEER system that is delivered through a vein in the leg, allowing for valve repair without the need for open-heart surgery, making it suitable for patients who might be at greater risk due to age or pre-existing health conditions. The device operates by using clips to grasp and bring together the leaflets of the tricuspid valve, thereby decreasing regurgitation and enhancing blood flow.
In July 2024, Edwards Lifesciences, a US-based provider of structural heart disease therapies and critical care monitoring technologies, acquired JenaValve Technology and Endotronix for approximately USD 1.2 billion. Through this acquisition, Edwards aims to broaden its structural heart portfolio by entering new therapeutic areas, strengthening its innovation pipeline, and addressing unmet needs in aortic regurgitation and heart failure care. JenaValve Technology, based in Germany, develops transcatheter aortic valve replacement solutions for aortic regurgitation, while Endotronix, a US-based company, provides implantable hemodynamic monitoring systems and digital heart failure management platforms.
Major companies operating in the structural heart market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Lepu Medical Technology Co. Ltd., LivaNova PLC, Venus Medtech (Hangzhou) Inc., CryoLife Inc., Endologix Inc., Braile Biomedica, JenaValve Technology Inc., Corvia Medical Inc., On-X Life Technologies Inc., Symetis SA, Micro Interventional Devices Inc., CardioKinetix Inc., Tendyne Holdings Inc., Neovasc Inc., NVT AG, Biomerics LLC, Shockwave Medical Inc., HLT Medical, Q'Apel Medical Inc., Z-Medical GmbH + Co. KG
North America was the largest region in the structural heart market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the structural heart market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the structural heart market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The structural heart market consists of revenues earned by entities by providing services such as patient evaluation, diagnosis, treatment planning, surgical or interventional procedures, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The structural heart market also includes sales of transcatheter heart valves, closure devices, and implantable devices that are used during procedures. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Structural Heart Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses structural heart market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for structural heart ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The structural heart market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.